Totally agree. As many have mentioned before, you can't actively market and sell a medical device until it is FDA approved. I'm not a lawyer but I would think they need to be careful on what they release from a product perspective in PR's. IF ISRG can prove that disclosing information about Titan's product has caused hospitals to delay buying robots until Titan's product gets FDA approval that will not be good for Titan long term. I do agree that many of the annoucements they provided yesterday and today, instead of 3-4 updates on one PR, they could have released each of these as they happened and kept momentum when we were in the $2 range.
What I am wondering is does the 2nd round of financing allow them to spend more money earlier with Ximedica. I sure hope so. I thought I read Ximedica has 60+ people working on the Titan project, but what if with the new funding, Ximedica can have 80 or 100 people working to get the development done faster. It really is amazing that Titan has access to Ximedica. There is no way they would be able to match the level of expertise by themselves without Ximedica. If this was all done in-house the burn rate would be dramatically higher to fund Titan and keep the lights on.
News 
Market Data 
Discover 
AI
